Drug Profile
PUR 1800
Alternative Names: PUR-1800; RV-1162Latest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator RespiVert
- Developer Pulmatrix; RespiVert
- Class Anti-inflammatories; Antibronchitics; Antineoplastics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease
- Preclinical Lung cancer
Most Recent Events
- 12 May 2023 PUR 1800 is available for licensing as of 12 May 2023. https://ir.pulmatrix.com/2023-05-12-Pulmatrix-Announces-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update
- 24 Feb 2023 Adverse events data and pharmacokinetics data from a phase Ib trial in Chronic obstructive pulmonary disease presented at the at the American Academy of Allergy, Asthma, & Immunology (AAAAI-2023)
- 21 Mar 2022 Top-line safety, pharmacokinetic and efficacy data from a phase Ib trial in Chronic obstructive pulmonary disease released by Pulmatrix